Actavis pays $40mm for option to acquire Rhythm Health; option is exercised
Executive Summary
Irish specialty pharmaco Actavis PLC received an exclusive option to buy Rhythm Pharmaceuticals Inc.’s wholly owned Rhythm Health Inc. subsidiary, which is focused on the development of Phase II relamorelin (RM131) for diabetic gastroparesis and other gastrointestinal conditions.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Payment Includes Cash for Equity
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice